Efficacy And Safety clinical trials

Explore recruiting efficacy and safety clinical trials.

Recruiting efficacy and safety studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Efficacy And Safety trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma

Italy, Spain, Czechia, Poland, Germany, Latvia +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)

Germany, Netherlands, France, Spain, Italy, Norway +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)

Hungary, Czechia, Portugal, Spain, Poland, Bulgaria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, parallel-group, randomized, double-blind, 4-arm, placebo-controlled, multicenter study with risankizumab as active reference arm, to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-α inhibitors

Spain, Czechia, Bulgaria, Poland, Hungary, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

Germany, Belgium, Netherlands, Denmark, Spain, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy And Safety trials by city

Efficacy And Safety in Toronto Efficacy And Safety in Vancouver Efficacy And Safety in Montreal Efficacy And Safety in Calgary Efficacy And Safety in Edmonton Efficacy And Safety in Ottawa Efficacy And Safety in Winnipeg Efficacy And Safety in Quebec City Efficacy And Safety in Hamilton Efficacy And Safety in Kitchener Efficacy And Safety in London Efficacy And Safety in Halifax Efficacy And Safety in New York Efficacy And Safety in Los Angeles Efficacy And Safety in Chicago Efficacy And Safety in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease